Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.

Landau SM, Horng A, Fero A, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2016 Apr 12;86(15):1377-1385. doi: 10.1212/WNL.0000000000002576. Epub 2016 Mar 11.

2.

Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.

Schreiber S, Landau SM, Fero A, Schreiber F, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

JAMA Neurol. 2015 Oct;72(10):1183-90. doi: 10.1001/jamaneurol.2015.1633.

PMID:
26280102
3.

Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures.

Apostolova LG, Hwang KS, Avila D, Elashoff D, Kohannim O, Teng E, Sokolow S, Jack CR, Jagust WJ, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2015 Feb 17;84(7):729-37. doi: 10.1212/WNL.0000000000001231. Epub 2015 Jan 21.

4.

Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression.

Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Schöll M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2015 Feb 3;84(5):508-15. doi: 10.1212/WNL.0000000000001209. Epub 2015 Jan 7.

5.

Predicting missing biomarker data in a longitudinal study of Alzheimer disease.

Lo RY, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2012 May 1;78(18):1376-82. doi: 10.1212/WNL.0b013e318253d5b3. Epub 2012 Apr 4.

6.

Predicting MCI outcome with clinically available MRI and CSF biomarkers.

Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Oct 25;77(17):1619-28. doi: 10.1212/WNL.0b013e3182343314. Epub 2011 Oct 12.

7.

Longitudinal change of biomarkers in cognitive decline.

Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Oct;68(10):1257-66. doi: 10.1001/archneurol.2011.123. Epub 2011 Jun 13.

8.

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Jan 4;76(1):69-79. doi: 10.1212/WNL.0b013e318204a397. Epub 2010 Dec 1.

9.

Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach.

Vounou M, Nichols TE, Montana G; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 Nov 15;53(3):1147-59. doi: 10.1016/j.neuroimage.2010.07.002. Epub 2010 Jul 17.

10.

Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment.

Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC; Alzheimer's Disease Neuroimaging Initiative investigators.

Neurobiol Aging. 2010 Aug;31(8):1452-62, 1462.e1-2. doi: 10.1016/j.neurobiolaging.2010.04.011.

11.

Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease.

Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, Jiang T; Alzheimer's Disease Neuroimaging Initiative.

Neuroreport. 2010 Aug 23;21(12):802-7. doi: 10.1097/WNR.0b013e32833ccaf4.

12.

Voxelwise genome-wide association study (vGWAS).

Stein JL, Hua X, Lee S, Ho AJ, Leow AD, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Dechairo BM, Potkin SG, Weiner MW, Thompson P; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 Nov 15;53(3):1160-74. doi: 10.1016/j.neuroimage.2010.02.032. Epub 2010 Feb 17.

13.

A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T).

Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 May 1;50(4):1427-37. doi: 10.1016/j.neuroimage.2010.01.064. Epub 2010 Jan 28.

14.

Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort.

Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage. 2010 Nov 15;53(3):1051-63. doi: 10.1016/j.neuroimage.2010.01.042. Epub 2010 Jan 25.

15.

Subregional neuroanatomical change as a biomarker for Alzheimer's disease.

Holland D, Brewer JB, Hagler DJ, Fennema-Notestine C, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20954-9. Erratum in: Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6551. Fenema-Notestine, Christine [corrected to Fennema-Notestine, Christine].

16.

Giving uridine and/or docosahexaenoic acid orally to rat dams during gestation and nursing increases synaptic elements in brains of weanling pups.

Cansev M, Marzloff G, Sakamoto T, Ulus IH, Wurtman RJ.

Dev Neurosci. 2009;31(3):181-92. doi: 10.1159/000193394. Epub 2009 Jan 15.

PMID:
19145070
17.

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study.

JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774.

18.

Multi-modal imaging predicts memory performance in normal aging and cognitive decline.

Walhovd KB, Fjell AM, Dale AM, McEvoy LK, Brewer J, Karow DS, Salmon DP, Fennema-Notestine C; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Jul;31(7):1107-21. doi: 10.1016/j.neurobiolaging.2008.08.013. Epub 2008 Oct 5.

19.

Synaptic proteins and phospholipids are increased in gerbil brain by administering uridine plus docosahexaenoic acid orally.

Wurtman RJ, Ulus IH, Cansev M, Watkins CJ, Wang L, Marzloff G.

Brain Res. 2006 May 9;1088(1):83-92. Epub 2006 Apr 21.

PMID:
16631143

Supplemental Content

Loading ...
Support Center